TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01775761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 1
Description: A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 2
Description: A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Period 3
Description: A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
Study: NCT04071223

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Scan
Description: Undergo bone scan

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cabozantinib S-malate
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET or NaF-PET

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo FDG-PET or NaF-PET
Study: NCT02752776

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Secukinumab
Description: Secukinumab was used as commercially available PFS of 150 mg. Patients received PFS at the site and were instructed to administer Secukinumab as needed (300 mg each application).
Study: NCT00317499

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01841762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macitentan
Description: Macitentan tablet, dose of 10 mg, once daily
Study: NCT03659175

Intervention type: OTHER
Intervention: SIBO
Description: SIBO: Small intestinal bacterial overgrowth, refers to a bacterial overgrowth due to organic or functional stasis in small intestine, leading to the change in number or types of bacteria in small intestine.
Study: NCT01812317

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forearm Vascular Study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Forearm Vascular Study
Description: Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Badimon Chamber Study
Description: Ex-vivo assessment of thrombus formation using the Badimon Chamber

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Badimon Chamber Study
Description: Ex-vivo assessment of thrombus formation using the Badimon Chamber
Study: NCT03449654

Intervention type: DRUG
Group type: OTHER
Intervention: Liraglutide
Description: Liraglutid

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo (for liraglutide)
Description: Placebo (for liraglutide)
Study: NCT02050217

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neurally Adjusted Ventilatory Assist
Study: NCT00730795

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's candidate Mycobacterium tuberculosis vaccine 692342
Description: Intramuscular injection, 3 doses at 0, 1, 2 months Different antigen doses (low and high)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK's candidate Mycobacterium tuberculosis vaccine 692342
Description: Intramuscular injection, 3 doses at 0, 1, 2 months Different antigen doses (low and high)
Study: NCT04373811

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung ultrasound
Description: Lung ultrasound will be performed in 12 thorax area: anterior, lateral and posterior, each area divided in superior and inferior area, for each hemithorax.~Lung Ultrasound Score (lung aeration) will be recorded using a convex probe with a transverse view. Presence of pleural thickening and subpleural consolidations will be recorded.

Intervention type: DIAGNOSTIC_TEST
Intervention: Muscle ultrasound
Description: Diaphragm ultrasound will be performed using intercostal view with a linear probe at the zone of apposition for assessing diaphragm thickness and thickening and subcostal anterior view with convex probe to assess diaphragm excursion.~Thickness of vastus intermedius, rectus femori and tibialis anterior will be measured using ultrasound linear probe. Cross-sectionnal area and echogeneicity of rectus femori and tibialis anterior will be measured using ultrasound linear probe. Penation angle of rectus femori will be assessed using ultrasound linear probe.
Study: NCT00795080

Intervention type: PROCEDURE
Intervention: Dynamic cervical MRI scans
Description: Serial MRI examination with the neck in flexion and extension to document changes in the cord compression and cerebral spinal fluid (CSF)

Intervention type: PROCEDURE
Intervention: Dynamic cervical MRI scans
Description: Serial MRI examination with the neck in flexion and extension to document changes in the cord compression and cerebral spinal fluid (CSF)

Intervention type: PROCEDURE
Intervention: Dynamic cervical MRI scans
Description: Serial MRI examination with the neck in flexion and extension to document changes in the cord compression and cerebral spinal fluid (CSF)
Study: NCT02918474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: Use decision making tool

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT03867201

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Erenumab
Description: Administered by pre-filled syringe

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by pre-filled syringe
Study: NCT02355184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO 140 350mg weekly SQ injection.
Description: CCR5 Antagonist
Study: NCT00217893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling
Description: One-on-one behavioral counseling with pre-teen child; 8 to 10 weekly or bi-weekly sessions; focus on identifying sources of exposure to ETS and means to avoid exposure; goal-setting, role-playing, monitoring progress, feedback includes reported info and urine cotinine level.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Urine Cotinine Feedback
Description: Urine collected from child at each weekly/bi-weekly counseling session; cotinine level discussed at subsequent session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingent Incentives
Description: Child earns small prizes for on-task behavior in sessions, plus earns tokens redeemable for other prizes based on reduction in ETS exposure (reported and cotinine level).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual education program
Description: Participants will receive the usual education about ETS.
Study: NCT03095560

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRVANA
Description: Nirvana is the first device based on optoelectronic infrared sensors, though which the patient can simply interact through his movements. The rehabilitation exercises with audio-visual stimuli and feedback involve the perceptual-cognitive skills of patients, resulting in a motivational training. Several modes and increasing levels of difficulty characterize each exercise, so the therapist can use a pre-defined rehabilitative solution or new ones, according to patient's needs. The results achieved during rehabilitation allow the therapist to evaluate the patient's actual progress, and then to modify the rehabilitation program. The system is connected to a projector or a big screen (put in front of the patient), reproducing an interactive series of exercises (for trunk, upper and lower limbs, and cognition), thanks to an infrared video camera analyzing the patient's movements, it creates interactivity.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIRVANA
Description: Nirvana is the first device based on optoelectronic infrared sensors, though which the patient can simply interact through his movements. The rehabilitation exercises with audio-visual stimuli and feedback involve the perceptual-cognitive skills of patients, resulting in a motivational training. Several modes and increasing levels of difficulty characterize each exercise, so the therapist can use a pre-defined rehabilitative solution or new ones, according to patient's needs. The results achieved during rehabilitation allow the therapist to evaluate the patient's actual progress, and then to modify the rehabilitation program. The system is connected to a projector or a big screen (put in front of the patient), reproducing an interactive series of exercises (for trunk, upper and lower limbs, and cognition), thanks to an infrared video camera analyzing the patient's movements, it creates interactivity.
Study: NCT03126162

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: InstilIing normal saline into bladder
Description: Backfilling the bladder with 200 mL of normal saline immediately postoperatively, prior to foley catheter removal, after same-day total laparoscopic hysterectomy can potentially increase time to first spontaneous void and time to discharge.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removal of foley catheter
Description: Removal of the foley catheter is routinely performed after same-day laparoscopic hysterectomy

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Removal of foley catheter
Description: Removal of the foley catheter is routinely performed after same-day laparoscopic hysterectomy
Study: NCT03706430

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse CO-Oximeter sensor
Description: Investigational Pulse CO-Oximeter sensor will measure hemoglobin (SpHb), Pulse Rate (PR), Perfusion Index (Pi), Methemoglobin (SpMet), Pleth Variability Index (PVi), RPVi, etc.
Study: NCT03348930

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tolcapone 200 MG
Description: All eligible study subjects will go through a 2-week treatment phase during which they will begin tolcapone at 100mg twice a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolcapone 200 MG
Description: All eligible study subjects will go through a 2-week treatment phase during which they will begin tolcapone at 100mg twice a day.
Study: NCT04071223

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04525768

Intervention type: DIAGNOSTIC_TEST
Intervention: JAK2 mutation test
Description: Patients with portal caver cavernoma will be divided into two groups by the result of JAK2 mutation test

Intervention type: DIAGNOSTIC_TEST
Intervention: JAK2 mutation test
Description: Patients with portal caver cavernoma will be divided into two groups by the result of JAK2 mutation test
Study: NCT02475265

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estradiol 0.045 mg/levonorgestrel 0.015mg
Study: NCT03148860

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: subjects will receive once weekly 15 mg (3 capsules) MTX

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: subjects will receive once weekly 15 mg (3 capsules) MTX

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: subject will receive Ustekinumab open-label over a treatment period of 52 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab
Description: subject will receive Ustekinumab open-label over a treatment period of 52 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ustekinumab
Description: subject will receive Ustekinumab open-label over a treatment period of 52 weeks
Study: NCT04071223

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radium Ra 223 Dichloride
Description: Given IV
Study: NCT00961025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-1229
Description: single dose study : DA-1229 1.25,2.5,5,10,20,40,60mg~multiple dose study : DA-1229 5,10,20,40mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT00003137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study: NCT01511796

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: upper limb rehabiliation
Description: 3 months upper rehabilation (twice a week) and then 3 more months upper limb rehabitation ( twice a week)
Study: NCT02013596

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEAS pretreatment
Description: Electric stimulation was given through electrode attached to specific acupoints for 30mins before anesthesia induction

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEAS treatment
Description: Transcutaneous Electrical Acupoint Stimulation was given to the patient at the same time of the start of anesthesia induction for 30mins
Study: NCT03148860

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab
Description: subject will receive Ustekinumab open-label over a treatment period of 52 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subjects will receive once weekly 3 capsules PLC to MTX

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subjects will receive once weekly 3 capsules PLC to MTX
Study: NCT04678921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ210001
Description: human anti-C5aR monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ210001
Description: human anti-C5aR monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ210001
Description: human anti-C5aR monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ210001
Description: human anti-C5aR monoclonal antibody
Study: NCT04418128

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nafamostat Mesylate
Description: The Nafamostat mesilate group received continuous intravenous infusion of 0.1-0.2 mg/kg/h of nafamostat mesilate mixed with 5% DW.
Study: NCT03502070

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: One dose (4 capsules) of placebo

Intervention type: DEVICE
Group type: OTHER
Intervention: Tobi Podhaler
Description: The placebo capsule has to be released from the blister card and inserted into the Podhaler device. The device is then actuated and the study drug is inhaled according to the instructions for use
Study: NCT00482677

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: temozolomide
Description: Temozolomide (concurrent with radiation) 75 mg/m2 PO 3 weeks once a day, daily, from the first day to the last day of radiotherapy, but for no longer than 28 days, and then adjuvantly for up to 12 cycles (150 mg/m2 for the first 5 days of each cycle). Adjuvant TMZ may be escalated to 200mg/m2 in C2 onward if appropriate.

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: DNA methylation analysis
Description: A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: DNA methylation analysis
Description: A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: prior to randomization until end of study
Study: NCT02098018

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program 2
Description: A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
Study: NCT00482677

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: quality-of-life assessment
Description: prior to randomization until end of study

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation
Description: Short course radiotherapy
Study: NCT02098018

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Program 1
Description: A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
Study: NCT01609816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Patients receive dasatinib PO every day (QD) for 6 months.
Study: NCT00228696

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: none, screening only
Description: Screening protocol with no intervention
Study: NCT00508443

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Three radiation treatments guided by the CT-on-Rails or Trilogy procedure over a period of 2 weeks. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.
Study: NCT00909480

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Treat-to-target (individually adjusted dose) titration according to titration algorithm.~S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: Treat-to-target (individually adjusted dose) titration according to titration algorithm.~S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued
Study: NCT00861601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag 12.5 milligrams (mg) tablet
Description: eltrombopag 12.5 mg tablet once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag 12.5 milligrams (mg) tablet
Description: eltrombopag 12.5 mg tablet once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag 25 mg tablet
Description: eltrombopag 25 mg tablet once a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eltrombopag 25 mg tablet
Description: eltrombopag 25 mg tablet once a day
Study: NCT00006002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaxanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaxanib
Study: NCT04099368

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Musical pitch training
Description: Crossover design with one group receiving musical training as rehabilitation, second group receiving visual training first as a control rehabilitation.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Musical pitch training
Description: Crossover design with one group receiving musical training as rehabilitation, second group receiving visual training first as a control rehabilitation.
Study: NCT00329537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (Leukine)
Description: Self-subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Self-subcutaneous injection
Study: NCT03128177

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary sodium
Description: High (6 g) versus low (1.5 g) sodium diet

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary sodium
Description: High (6 g) versus low (1.5 g) sodium diet
Study: NCT00136136

Intervention type: PROCEDURE
Intervention: Registration of the bispectral index and spectral edge frequency
Description: Registration of the bispectral index and spectral edge frequency

Intervention type: PROCEDURE
Intervention: Registration of the bispectral index and spectral edge frequency
Description: Registration of the bispectral index and spectral edge frequency

Intervention type: PROCEDURE
Intervention: Registration of the bispectral index and spectral edge frequency
Description: Registration of the bispectral index and spectral edge frequency
Study: NCT01120158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (IV) 10 mg/kg on day 1 and day 15. Treatment repeats every 28 days. Therapy will continue until maximum response, disease progression or unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (IV) 120 mg/m2,on day 1 and day 15. Treatment repeats every 28 days Therapy will continue until maximum response, disease progression or unacceptable toxicity.
Study: NCT03311958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab, IV, 240 mg
Description: Patients would be given an infusion of 240 mg nivolumab over 30 min
Study: NCT03911427

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active oat beverage
Description: Powder packaged in sachets, mixed with water and consumed 3 times per day for 1 month

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control rice beverage
Description: Powder packaged in sachets, mixed with water and consumed 3 times per day for 1 month